Research Center, Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia.
University of Wollongong, Wollongong, Australia.
Eur J Med Res. 2020 Nov 25;25(1):61. doi: 10.1186/s40001-020-00462-x.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from China in December 2019 and has presented as a substantial and serious threat to global health. We aimed to describe the clinical, epidemiological, and laboratory findings of patients in Saudi Arabia infected with SARS-CoV-2 to direct us in helping prevent and treat coronavirus disease 2019 (COVID-19) across Saudi Arabia and around the world.
Clinical, epidemiological, laboratory, and radiological characteristics, treatment, and outcomes of pediatric and adult patients in five hospitals in Riyadh, Saudi Arabia, were surveyed in this study.
401 patients (mean age 38.16 ± 13.43 years) were identified to be SARS-CoV-2 positive and 80% of cases were male. 160 patients had moderate severity and 241 were mild in severity. The most common signs and symptoms at presentation were cough, fever, fatigue, and shortness of breath. Neutrophil and lymphocyte counts, aspartate aminotransferase, C-reactive protein, and ferritin were higher in the COVID-19 moderate severity patient group. Mild severity patients spent a shorter duration hospitalized and had slightly higher percentages of abnormal CT scans and X-ray imaging.
This study provides an understanding of the features of non-ICU COVID-19 patients in Saudi Arabia. Further national collaborative studies are needed to streamline screening and treatment procedures for COVID-19.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)于 2019 年 12 月在中国出现,对全球健康构成了重大而严重的威胁。我们旨在描述在沙特阿拉伯感染 SARS-CoV-2 的患者的临床、流行病学和实验室发现,以指导我们在沙特阿拉伯和世界各地预防和治疗 2019 年冠状病毒病(COVID-19)。
本研究调查了沙特阿拉伯利雅得五家医院的儿科和成年患者的临床、流行病学、实验室和影像学特征、治疗和结局。
共确定 401 例(平均年龄 38.16±13.43 岁)患者 SARS-CoV-2 阳性,80%的病例为男性。160 例患者为中度严重,241 例为轻度严重。就诊时最常见的体征和症状是咳嗽、发热、乏力和呼吸急促。中性粒细胞和淋巴细胞计数、天门冬氨酸氨基转移酶、C 反应蛋白和铁蛋白在 COVID-19 中度严重患者组中较高。轻度严重患者住院时间较短,CT 扫描和 X 线成像异常的百分比略高。
本研究提供了对沙特阿拉伯非 ICU COVID-19 患者特征的了解。需要进一步进行全国性合作研究,以简化 COVID-19 的筛查和治疗程序。